An Eight Week, Double-Blind, Randomized, Multicenter, Parallel Group, Active-Controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension.

Trial Profile

An Eight Week, Double-Blind, Randomized, Multicenter, Parallel Group, Active-Controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Aliskiren (Primary) ; Ramipril
  • Indications Essential hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Jan 2012 Results published in Hypertension Research.
    • 19 Jun 2010 Results presented at the 17th World Congress of Cardiology.
    • 13 Jun 2009 Results presented at the 19th European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top